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Introduction
============

It is well known that patients with peripheral artery disease (PAD) have a markedly increased risk for cardiovascular events and advanced atherosclerotic disease^[@bib1]--[@bib3])^. However, mortality and morbidity rates of cardiovascular disease are not constant in PAD. Interestingly, the prevalence of cardiovascular events and any cause of death are significantly higher in patients with atherosclerotic PAD than in patients with Buerger disease, and the mortality rate in patients with Buerger disease is not higher than that in age-matched control subjects^[@bib1],\ [@bib4],\ [@bib5])^.

Intima-media thickness (IMT) is an established index of structural change of an artery. IMT, particularly that of the carotid, is associated with the presence of cardiovascular risk factors^[@bib6],\ [@bib7])^ and is an independent predictor of cardiovascular events^[@bib8]--[@bib10])^. Recently, we have shown that IMT of the brachial artery also serves as a surrogate marker for progression of atherosclerosis^[@bib11])^. However, there is little information on endothelial function and IMT of a leg artery in patients with PAD, including Buerger disease.

Endothelial function is initially impaired with progression of atherosclerosis, leading to cardiovascular events^[@bib12],\ [@bib13])^. Evaluation of flow-mediated vasodilatation (FMD) and nitroglycerine-induced vasodilation (NID) is useful for assessing vascular function^[@bib14]--[@bib20])^. Previous studies have shown that endothelial function assessed by FMD can serve as an independent predictor of cardiovascular events^[@bib21]--[@bib25])^. Several studies have demonstrated that not only FMD but also NID is impaired in subjects with cardiovascular risk factors, patients with coronary vascular disease, and patients with PAD^[@bib19],\ [@bib20],\ [@bib26]--[@bib28])^. Recently, we demonstrated that NID decreased in relation to cumulative cardiovascular risk factors and was therefore significantly correlated with cardiovascular risk factors as well as FMD and that impaired NID was an independent variable for critical limb ischemia^[@bib19],\ [@bib28])^. Vascular function assessed by NID per se also should predict cardiovascular outcomes.

Although some studies have shown interrelations between endothelial function assessed by FMD and that assessed by IMT in a general population, FMD and IMT were examined at different vasculatures, such as the brachial artery and common carotid artery in those studies^[@bib29]--[@bib31])^. There is no information on differences in IMT, FMD and NID of the peripheral artery between Buerger disease and atherosclerotic PAD. Therefore, in the present study, we evaluated FMD, NID, and IMT in the same leg artery in patients with Buerger disease and patients with atherosclerotic PAD.

Methods
=======

Subjects
--------

A total of 100 subjects (mean age, 58.9 ± 14.1 years), including 20 patients with Buerger disease (18 men and two women, mean age: 48.9 ± 14.4 years), and 30 patients with atherosclerotic PAD (22 men and eight women, mean age: 69.5 ± 7.8 years), 20 age-and sex-matched subjects without Buerger disease (Buerger control group: 19 men and one woman, mean age: 43.0 ± 5.1 years), and 30 age- and sex-matched patients without atherosclerotic PAD (atherosclerotic PAD control group: 20 men and 10 women, mean age: 65.7 ± 7.5 years), were enrolled. Buerger disease was diagnosed by the previously reported criteria, including results of physical examinations, clinical symptoms, angiographic findings, and results of arterial duplex scanning^[@bib32])^. To rule out other vasculitis and hypercoagulable states, rheumatoid factor, lupus anticoagulants, and serologic investigations were evaluated. Atherosclerotic PAD and Buerger disease were defined as current intermittent claudication with ankle-brachial index (ABI) \< 0.9, or chronic ischemic rest pain, ischemic ulcers, or gangrene attributed to objectively proven arterial occlusive disease, or history of previous intervention including angioplasty, bypass graft, and limb amputation. Diagnosis of limb ischemia was confirmed by angiography. Control subjects were matched sex and age, and had no PAD. Hypertension was defined as treatment with oral antihypertensive agents or systolic blood pressure of more than 140 mmHg, or diastolic blood pressure of more than 90 mmHg, in a sitting position on at least three different occasions without medication^[@bib33])^. Diabetes was defined according to the American Diabetes Association recommendation^[@bib34])^. Dyslipidemia was defined according to the third report of the National Cholesterol Education Program^[@bib35])^. We defined smokers as those who had ever smoked. Coronary heart disease included angina pectoris, myocardial infarction, and unstable angina. The vascular tests were performed without withholding medications. The ethical committees of our institutions approved the study protocol. Written informed consent for participation in the study was obtained from all subjects.

Study Protocol
--------------

We measured vascular responses to reactive hyperemia and sublingually administrated nitroglycerine in the popliteal artery without stenosis and in occluded arteries in subjects. Subjects fasted the previous night for at least 12 h. The study began at 8:30 AM. The subjects were kept in the prone position in a quiet, dark, air-conditioned room (constant temperature of 22°C--25°C) throughout the study. A 23-gauge polyethylene catheter was inserted into the left deep antecubital vein to obtain blood samples. Thirty minutes after maintaining the prone position, basal popliteal artery diameter and IMT were measured. Then, FMD was measured in the popliteal artery. After completion, we next measured NID with confirmation that the popliteal artery diameter had recovered to the baseline value. The observers were blind to the protocol of this study.

Measurement of Popliteal Artery IMT
-----------------------------------

The ultrasound unit Aloka-*α*7 (Aloka Co, Tokyo, Japan) equipped with a linear, phased-array high-frequency (13-MHz) transducer was used for scanning the popliteal artery. Ultrasound longitudinal images of the popliteal artery were acquired at the end of the diastole (defined as the R wave of an electrocardiogram), in which the far wall intima-media interface was clearly defined. The leading edge of the intima and the media-adventitia interface were traced as continuous lines. A total of 20 points over a 3-mm length of IMT in the 10-mm longitudinal image depicted in the analysis display were measured and the mean value per image was automatically calculated. IMT was measured at the same point in each different image. The average of mean values obtained from 10 cardiac cycles was defined as IMT of the popliteal artery. All of the duplex ultrasonography scans were performed by ultrasonograhic specialists.

The coefficient of variation for IMT was 4.9% in our laboratory.

Measurement of Vascular Function
--------------------------------

A high-resolution linear artery transducer was coupled to computer-assisted analysis software (Aloka-*α*7, ALOKA Co., Tokyo, Japan) that used an automated edge detection system for measurement of artery diameter. A blood pressure cuff was placed around the thigh. The target artery was scanned longitudinally. When the clearest B-mode image of the intimal interfaces between the lumen and vessel wall was obtained, the transducer was held at the same point throughout the scan by a special probe holder (MP-PH0001, ALOKA Co.) to ensure consistency of the image. A baseline image was acquired and blood floTable 1.Clinical Characteristics of The SubjectsVariableTotal (*n* = 100)Buerger disease No (*n* = 20)Buerger disease Yes (*n* = 20)*P* valueAtherosclerotic PAD No (*n* = 30)Atherosclerotic PAD Yes (*n* = 30)*P* valueAge, yr58.9 ± 14.143.0 ± 5.148.9 ± 14.40.0965.7 ± 7.569.5 ± 7.80.06Sex, men/women79/2119/118/20.5420/1022/80.57Body mass index, kg/m^2^22.7 ± 3.222.7 ± 3.022.4 ± 3.10.7523.7 ± 3.121.9 ± 3.20.03Systolic blood pressure, mmHg126.8 ± 19.8118.1 ± 8.7117.2 ± 16.70.84130.9 ± 17.8134.8 ± 24.10.49Diastolic blood pressure, mmHg74.5 ± 11.974.7 ± 7.470.2 ± 13.20.2077.6 ± 11.574.3 ± 13.30.31Heart rate, bpm72.5 ± 12.171.3 ± 9.968.8 ± 11.90.4869.3 ± 10.579.0 ± 13.0\< 0.01Total cholesterol, mg/dL172.8 ± 31.4178.4 ± 18.8171.3 ± 34.80.57175.0 ± 20.1170.3 ± 39.30.61Triglycerides, mg/dL116.1 ± 58.581.4 ± 26.9125.9 ± 67.10.07127.7 ± 67.3110.2 ± 47.70.28High-density lipoprotein cholesterol, mg/dL56.0 ± 17.263.1 ± 20.549.0 ± 11.30.0357.9 ± 12.756.8 ± 21.80.83Low-density lipoprotein cholesterol, mg/dL98.0 ± 25.5100.0 ± 20.4102.4 ± 29.00.83100.1 ± 19.692.2 ± 29.30.27Glucose, mg/dL116.4 ± 35.697.9 ± 16.6101.1 ± 20.40.69114.6 ± 21.8133.9 ± 48.60.07Ankle-brachial index1.00 ± 0.241.20 ± 0.050.82 ± 0.25\< 0.011.15 ± 0.070.83 ± 0.21\< 0.01Rutherford class    0, n (%)55 (55.0)20 (100.0)4 (20.0)\< 0.0130 (100.0)1 (3.3)\< 0.01    1, n (%)5 (5.0)0 (0.0)4 (20.0)0.010 (0.0)1 (3.3)0.24    2, n (%)6 (6.0)0 (0.0)2 (10.0)0.090 (0.0)4 (13.3)0.02    3, n (%)7 (7.0)0 (0.0)1 (5.0)0.230 (0.0)6 (20.0)\< 0.01    4, n (%)5 (5.0)0 (0.0)1 (5.0)0.230 (0.0)4 (13.3)0.02    5, n (%)19 (19.0)0 (0.0)7 (35.0)\< 0.010 (0.0)12 (40.0)\< 0.01    6, n (%)3 (3.0)0 (0.0)1 (5.0)0.230 (0.0)2 (6.7)0.09Fontaine class    Stage I, n (%)55 (55.0)20 (100)4 (20.0)\< 0.013 (100)1 (3.3)\< 0.01    Stage II, n (%)18 (18.0)0 (0)7 (35.0)\< 0.010 (0)11 (36.6)\< 0.01    Stage III, n (%)5 (5.0)0 (0)1 (5.0)0.230 (0)4 (13.3)0.02    Stage IV, n (%)22 (22.0)0 (0)8 (40.0)\< 0.010 (0)14 (46.7)\< 0.01Medical history, n (%)    Hypertension57 (57.0)1 (5.0)3 (15.0)0.2825 (83.3)28 (93.3)0.22    Dyslipidemia32 (32.0)2 (10.0)4 (20.0)0.3715 (50.0)11 (36.7)0.30    Diabetes mellitus38 (38.0)0 (0.0)1 (5.0)0.2317 (56.7)20 (66.7)0.43    Previous coronary heart disease22 (22.0)0 (0.0)0 (0.0)ND7 (23.3)15 (50.0)0.03Smoker (current), %20 (20.0)4 (20.0)4 (20.0)1.08 (26.7)4 (13.3)0.19Smoker (past), %49 (49.0)8 (40.0)15 (75.0)0.0210 (33.3)16 (53.3)0.12Medications, n (%)    Calcium-channel blockers24 (24.0)0 (0.0)1 (5.0)0.2314 (46.7)9 (30.0)0.18    Renin angiotensin system inhibitors34 (34.0)1 (5.0)1 (5.0)1.014 (46.7)18 (60.0)0.30    Statins28 (28.0)2 (10.0)3 (15.0)0.6315 (50.0)8 (26.7)0.06    Medically treated diabetes29 (29.0)0 (0.0)0 (0.0)ND14 (46.7)15 (50.0)0.80PAD indicates peripheral arterial disease; ND, not detected.All results are presented as means ± SD.w was estimated by time averaging the pulsed Doppler velocity signal obtained from a sample volume. Then the blood pressure cuff was inflated to 50 mm Hg above systolic pressure for 5 min. Depth and gain setting were set to optimize the images of the arterial lumen wall interface. When the tracking gate was placed on the intima, the artery diameter was automatically tracked and the waveform of diameter changes over the cardiac cycle was displayed in real time using the FMD mode of the tracking system. This allowed the ultrasound images to be optimized at the start of the scan and the transducer position to be adjusted immediately for optimal tracking performance throughout the scan. Pulsed Doppler flow was assessed at baseline and during peak hyperemic flow, which was confirmed to occur within 15 s after cuff deflation. Blood flow velocity was calculated from the color Doppler data and was displayed as a waveform in real time. The baseline longitudinal image of the artery was acquired for 30 s and then the blood pressure cuff was inflated to 50 mm Hg above systolic pressure for 5 min. The longitudinal image of the artery was recorded continuously until 5 min after cuff deflation. Pulsed Doppler velocity signals were obtained for 20 s at baseline and for 10 s immediately after cuff deflation. Changes in brachial artery diameter were immediately expressed as per cent change relative to the vessel diameter before cuff inflation. FMD was calculated as the per cent change in peak vessel diameter from the baseline value. %FMD \[(peak diameter -- baseline diameter)/baseline diameter\] was used for analysis. Blood flow volume was calculated by multiplying the Doppler flow velocity (corrected for the angle) by heart rate and vessel cross-sectional area (-r^2^). Reactive hyperemia was calculated as the maximum percentage increase in flow after cuff deflation compared with baseline flow. After a 10-min period to allow baseline conditions of the artery to be reestablished, another baseline scan was performed.

The response to nitroglycerine was used for assessment of endothelium-independent vasodilation. NID was measured as described previously^[@bib28])^. Briefly, after acquiring baseline rest images for 30 s, a sublingual tablet (75 µg nitroglycerine) was given, and images of the artery were recorded continuously until the dilation reached a plateau after administration of nitroglycerine. Subjects who had received nitrate treatment and subjects in whom the sublingually administered nitroglycerine tablet did not dissolved during the measurement, were excluded from this study. NID was automatically calculated as a per cent change in peak vessel diameter from the baseline value. Percentage of NID \[(peak diameter -- baseline diameter)/baseline diameter\] was used for analysis.

The coefficient of variation for the baseline diameter was 2.9% in our laboratory.

Analytical Methods
------------------

Samples of venous blood were placed in tubes containing sodium ethylenediamine tetraacetic acid (1 mg/mL) and in polystyrene tubes. The ethylenediamine tetraacetic acid-containing tubes were chilled promptly in an ice bath. Plasma was immediately separated by centrifugation at 3100 g for 10 min at 4°C, and serum was separated by centrifugation at 1000 g for 10 min at room temperature. Samples were stored at −80°C until the time of assay. Serum concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glucose, and electrolytes were determined by routine chemical methods.

Statistical Analysis
--------------------

Results are presented as the means ± standard deviation (SD) for continuous variables and as percentages for categorical variables. Statistical significance was set at a level of *P* \< 0.05. Comparisons between groups were carried out using *P* for trend analysis. Unpaired Student\'s *t*-test was used for group comparisons. The data were processed using the software package Stata version 9 (Stata Co, College Station, TX, USA).

Results
=======

Baseline Clinical Characteristics
---------------------------------

The baseline clinical characteristics are summarized in **[Table 1](#T1){ref-type="table"}**. Of the 20 patients with Buerger disease, 18 (90.0%) were men and two (10.0%) were women; three (15.0%) had hypertension, four (20.0%) had dyslipidemia, one (5.0%) had diabetes mellitus, four (20.0%) were current smokers and none had previous coronary heart disease. Serum concentration of high-density lipoprotein cholesterol and ABI were significantly lower in the Buerger group than in the control group. There were no significant differences in other parameters between the two groups.

Of the 30 subjects with atherosclerotic PAD, 22 (73.3%) were men and eight (26.7%) were women; 28 (93.3%) had hypertension, 11 (36.7%) had dyslipidemia, 20 (66.7%) had diabetes mellitus, four (13.3%) were current smokers, and 15 (50.0%) had previous coronary heart disease. Heart rate, serum concentration of glucose, and ratio of previous coronary heart disease were significantly higher in the atherosclerotic PAD group than in the atherosclerotic PAD control group. Body mass index and ABI were significantly lower in the atherosclerotic PAD group than in the atherosclerotic PAD control group. There were no significant differences in other parameters between the two groups.

Vascular Function and Structure in Patients with Buerger Disease and Patients with Atherosclerotic PAD
------------------------------------------------------------------------------------------------------

There were no significant differences in FMD and NID between the Buerger group and control group (FMD: Buerger group, 5.7% ± 1.8%; control group, 6.1% ± 0.9%; *P* = 0.40; and NID: Buerger group, 8.6% ± 3.6%; control group, 9.8% ± 1.7%; *P* = 0.19, **[Fig. 1](#F1){ref-type="fig"}**). IMT was significantly larger in the Buerger group than in the control group (Buerger group, 0.63 ± 0.20 mm; control group, 0.50 ± 0.07 mm; *P* = 0.01, **[Fig. 2](#F2){ref-type="fig"}**).

![Bar graphs show flow-mediated vasodilation and nitroglycerine-induced vasodilation in patients with and without Buerger disease.](jat-23-1261-g001){#F1}

![Bar graph shows the brachial intima-media thickness in patients with and without Buerger disease.](jat-23-1261-g002){#F2}

FMD and NID were significantly smaller in the atherosclerotic PAD group than in the control group (FMD: atherosclerotic PAD group, 3.9% ± 1.1%; control group, 5.0% ± 1.8%; *P* \< 0.01 and NID: atherosclerotic PAD group, 6.1% ± 2.0%; control group, 8.4% ± 2.1%; *P* \< 0.01, **[Fig. 3](#F3){ref-type="fig"}**). IMT was significantly larger in the atherosclerotic PAD group than in the control group (atherosclerotic PAD group, 0.80 ± 0.22 mm; control group, 0.65 ± 0.14 mm; *P* \< 0.01, **[Fig. 4](#F4){ref-type="fig"}**).

![Bar graphs show flow-mediated vasodilation and nitroglycerine-induced vasodilation in patients with and without atherosclerotic peripheral arterial disease.](jat-23-1261-g003){#F3}

![Bar graph shows the brachial intima-media thickness in patients with and without atherosclerotic peripheral arterial disease.](jat-23-1261-g004){#F4}

Discussion
==========

In the present study, we demonstrated that IMT of the popliteal artery was increased both in patients with Buerger disease and patients with atherosclerotic PAD compared with those in control groups. FMD and NID of the popliteal artery were impaired in patients with atherosclerotic PAD but not in patients with Buerger disease. These findings suggest that vascular function of a leg artery is preserved in patients with Buerger disease and that both vascular function and vascular structure of a leg artery are impaired in patients with atherosclerotic PAD.

It is well known that patients with PAD, particularly atherosclerotic PAD, have a high prevalence of cardiovascular morbidity and mortality^[@bib1],\ [@bib2])^. Atherosclerosis progressively develops with aging in patients with atherosclerotic PAD. Endothelial dysfunction is the initial step in the pathogenesis of atherosclerosis, resulting in cardiovascular complications^[@bib12],\ [@bib13])^. Recently, we reported that both FMD and NID were impaired in patients with PAD^[@bib19])^. In addition, brachial IMT was correlated with NID, suggesting that vascular smooth muscle function is also impaired in relation to increased brachial IMT^[@bib11])^. In the present study, in the popliteal artery also, IMT was increased and FMD and NID were impaired in patients with atherosclerotic PAD, suggesting that atherosclerotic PAD has an advanced vascular failure. Severe vascular failure may contribute to the high cardiovascular morbidity and mortality rates in atherosclerotic PAD.

On the other hand, it has been reported that there is no significant difference in the rate of mortality between patients with Buerger disease and normal populations^[@bib4],\ [@bib5])^. Some investigators have reported that the survival rate of patients with Buerger disease is significantly lower than that in the general population^[@bib4],\ [@bib36])^. Cumulative survival rate was significantly higher in patients with Buerger disease than in patients with atherosclerotic PAD^[@bib1],\ [@bib5],\ [@bib37])^. In the present study, vascular function, including endothelial function and vascular smooth muscle function, were not impaired in patients with Buerger disease. In addition, in a previous study, we have shown that confounding factors for endothelial function, such as oxidative stress markers, number of endothelial progenitor cells, and cell migration response to vascular endothelial growth factor, other than an inflammation marker, are similar in patients with Buerger disease and healthy controls^[@bib38])^. Interestingly, IMT in the popliteal artery was larger in the Buerger group than in the control group, while IMT in the popliteal artery was smaller in the Buerger group than in the atherosclerotic PAD group. There has been no information on IMT in leg arteries of patients with Buerger disease. The precise reason for the increase in IMT in the popliteal artery in Buerger disease remains unclear.

In conclusion, patients with Buerger disease had normal vascular function but large IMT compared with that in age- and sex-matched controls, and patients with atherosclerotic PAD had abnormal vascular function and large IMT compared with that in age- and sex-matched controls. Our results may partially explain why there are differences in the rates of morbidity and mortality of cardiovascular diseases between patients with Buerger disease and patients with atherosclerotic PAD. Further studies are needed to evaluate vascular function and structure, and outcomes during a long-term follow-up period in patients with Buerger disease and patients with atherosclerotic PAD.
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